Both in Biotechnology
Estrella Immunopharma vs Pluri
Over the past year ESLA returned −80.6% and PLUR returned −65.3%; their daily moves had a correlation of 0.11.
ESLA −80.6% PLUR −65.3%Growth of $1, one year, split-adjusted
| Metric | ESLA | PLUR |
|---|---|---|
| Price | $0.4435 | $1.23 |
| Market cap | $19.3M | $16.6M |
| Today | +6.10% | −3.15% |
| 1 month | +3.4% | +24.2% |
| 6 months | −65.9% | −62.7% |
| Year to date | −71.6% | −58.9% |
| 1 year | −85.5% | — |
| Revenue growth (YoY) | — | −15.8% |
| Gross margin | — | 58.5% |
| Net margin | — | −1755.2% |
| P/E (TTM) | — | — |
| Price / sales | — | 16.4× |
| Net cash | $146.7K | -$23.9M |
| Dividend yield | — | — |
| Volatility (60d) | 201.6% | 81.3% |
| Short % of float | 4.0% | 0.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).